Abbvie (ABBV) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $3.65
- EPS estimate
- $3.60
- EPS surprise
- +1.40%
- Revenue surprise
- +1.25%
- Revenue
- $17.0B
- Revenue estimate
- $16.8B
- Reported
- Jul 31, 2026
AbbVie reported Q2 2026 results on July 31, 2026. Earnings per share were $3.65, beating the $3.60 estimate by 1.40%. Revenue was $17.0 billion against a $16.8 billion consensus, a 1.25% beat. Compared with Q2 2025, EPS rose about 23% from $2.97 and revenue rose about 10% from $15.4 billion.
Annual EPS declined every year after 2022. It was $13.79 in 2022, $11.11 in 2023, $10.12 in 2024 and $10.00 in 2025. Revenue moved the other way after 2023, rising from about $54.3 billion that year to about $61.1 billion in 2025. The first half of 2026 adds up to $6.30 per share, about 16% more than a year earlier. Q2 2026 revenue was the highest in the table. The EPS high was $3.66 in Q3 2022 and the low was $1.86 in Q3 2025. Over the last 20 quarters, AbbVie beat the EPS estimate 18 times, with misses in Q1 2023 and Q4 2023.
AbbVie reported Q3 between October 27 and October 31 in each of the past five years. That points to late October 2026 for the next report. It will show whether the year-over-year gains of the first half continue.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 31, 2026 | $3.60 | $3.65 | +1.40% | $17.0B | SEC |
| Q1 2026 | Apr 29, 2026 | $2.59 | $2.65 | +2.23% | $15.0B | SEC |
| Q4 2025 | Feb 4, 2026 | $2.65 | $2.71 | +2.15% | $16.6B | SEC |
| Q3 2025 | Oct 31, 2025 | $1.77 | $1.86 | +5.34% | $15.8B | SEC |
| Q2 2025 | Jul 31, 2025 | $2.88 | $2.97 | +3.12% | $15.4B | SEC |
| Q1 2025 | Apr 25, 2025 | $2.38 | $2.46 | +3.39% | $13.3B | SEC |
| Q4 2024 | Jan 31, 2025 | $2.12 | $2.16 | +2.12% | $15.1B | SEC |
| Q3 2024 | Oct 30, 2024 | $2.92 | $3.00 | +2.74% | $14.5B | SEC |
| Q2 2024 | Jul 25, 2024 | $2.57 | $2.65 | +3.29% | $14.5B | SEC |
| Q1 2024 | Apr 26, 2024 | $2.25 | $2.31 | +2.46% | $12.3B | SEC |
| Q4 2023 | Feb 2, 2024 | $2.79 | $2.79 | −0.11% | $14.3B | SEC |
| Q3 2023 | Oct 27, 2023 | $2.87 | $2.95 | +2.87% | $13.9B | SEC |
| Q2 2023 | Jul 27, 2023 | $2.83 | $2.91 | +2.75% | $13.9B | SEC |
| Q1 2023 | Apr 27, 2023 | $2.51 | $2.46 | −1.95% | $12.2B | SEC |
| Q4 2022 | Feb 9, 2023 | $3.56 | $3.60 | +1.10% | $15.1B | SEC |
| Q3 2022 | Oct 28, 2022 | $3.57 | $3.66 | +2.43% | $14.8B | SEC |
| Q2 2022 | Jul 29, 2022 | $3.32 | $3.37 | +1.49% | $14.6B | SEC |
| Q1 2022 | Apr 29, 2022 | $3.14 | $3.16 | +0.59% | $13.5B | SEC |
| Q4 2021 | Feb 2, 2022 | $3.28 | $3.31 | +0.81% | $14.9B | SEC |
| Q3 2021 | Oct 29, 2021 | $3.21 | $3.33 | +3.62% | $14.3B | SEC |
Quarterly revenue
Frequently asked questions
When did Abbvie (ABBV) last report earnings?
Abbvie last reported on Jul 31, 2026, covering fiscal Q2 2026.
Did ABBV beat earnings estimates?
Yes. Abbvie reported EPS of $3.65 for Q2 2026 against a $3.60 estimate — a 1.40% beat.
How much revenue did ABBV report last quarter?
Abbvie reported $17.0B in revenue for Q2 2026, against a consensus estimate of $16.8B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.